44. Clinical benefit table: Orthovisc. Continuous outcome measures (2).

Study	Time	Treatment	Outcome	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Sezgin 2005	1‐4 wk	E: Orthovisc	WOMAC pain (5‐25 LIkert)	22	18.9	8.9	‐3.9 (I)	‐22.7% (I)
		C: Saline		19	17.2	11.1
Sezgin 2005	1‐4 wk	E: Orthovisc	WOMAC stiffness (2‐10 Likert)	22	6.5	3.4	‐2.0 (I)	‐44.4% (I)
		C: Saline		19	4.5	3.4
Sezgin 2005	1‐4 wk	E: Orthovisc	WOMAC physical function (17‐85 Likert)	22	64.1	32.2	‐20.9 (I)	‐41.8% (I)
		C: Saline		19	50.0	39.0
Sezgin 2005	1‐4 wk	E: Orthovisc	Flexion (degrees)	22	95.9	125.2	16.5 (I)	15.2% (I)
		C: Saline		19	108.4	121.2
Sezgin 2005	1‐4 wk	E: Orthovisc	25 metre walking time (sec)	22	43.1	26.4	‐11.2 (I)	‐35.6% (I)
		C: Saline		19	31.5	26.0
Sezgin 2005	1‐4 wk	E: Orthovisc	Knee cirumference (cm)	22	41.5	40.0	‐0.5 (I)	‐1.2% (I)
		C: Saline		19	41.3	40.3
Sezgin 2005	1‐4 wk	E: Orthovisc	Synovial fluid effusion volume (ml)	22	19.0	7.6	‐4.5 (I)	‐24.3% (I)
		C: Saline		19	18.5	11.6
Sezgin 2005	1‐4 wk	E: Orthovisc	Interleukin 6 level in synovial fluid (pg/ml)	22	42.8	22.3	‐3.0 (I)	‐5.8% (I)
		C: Saline		19	51.7	34.2
Sezgin 2005	1‐4 wk	E: Orthovisc	Interleukin 8 level in synovial fluid (pg/ml)	22	20.6	17.0	‐7.5 (I)	‐41.9% (I)
		C: Saline		19	17.9	21.8
Sezgin 2005	1‐4 wk	E: Orthovisc	Tumor necrosis factor alpha levels in synovial fluid (pg/ml)	22	77.0	58.7	‐5.5 (I)	‐6.8% (I)
		C: Saline		19	80.8	68.0
Neustadt 2005a	5‐13 wk	E: Orthovisc (4 injections)	WOMAC pain (0‐500 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (3 injections)	WOMAC pain (0‐500 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (4 injections)	WOMAC pain (0‐500 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (3 injections)	WOMAC pain (0‐500 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (4 injections)	Pain on standing (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (3 injections)	Pain on standing (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (4 injections)	Pain on standing (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (3 injections)	Pain on standing (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (4 injections)	Patient global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (3 injections)	Patient global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (4 injections)	Patient global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (3 injections)	Patient global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (4 injections)	Investigator global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	5‐13 wk	E: Orthovisc (3 injections)	Investigator global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (4 injections)	Investigator global score (0‐100 mm VAS)
		C: Arthrocentesis
Neustadt 2005a	14‐26 wk	E: Orthovisc (3 injections)	Investigator global score (0‐100 mm VAS)
		C: Arthrocentesis
Yentur 2003	1 wk	E: Orthovisc+lidocaine	Pain at rest (0‐4 point scale)	17	2.90	0.52	‐2.07 (I)	‐80.9% (I)
		C: Orthovisc		16	2.56	2.25
Yentur 2003	1 wk	E: Orthovisc+lidocaine	Pain/restrictions walking (0‐4 point scale)	17	2.35	0.88	‐1.10 (I)	‐46.4% (I)
		C: Orthovisc		16	2.37	2.00
Yentur 2003	1 wk	E: Orthovisc+lidocaine	Pain/restrictions going up or down stairs (0‐4 point scale)	17	2.60	0.88	‐1.47 (I)	‐56.1% (I)
		C: Orthovisc		16	2.62	2.37
Yentur 2003	1 wk	E: Orthovisc+lidocaine	Range of motion (degrees)	17	103.8	124.4	21.2 (I)	18.2% (I)
		C: Orthovisc		16	116.2	116.8
Karatosun 2005a	1‐4 wk	E: Orthovisc	Hospital for Special Surgery Knee Score	39	67.7	86.5	2.2 (I)	3.1% (I)
		C: Hylan G‐F 20		40	70.1	86.7
Karatosun 2005a	5‐13 wk	E: Orthovisc	Hospital for Special Surgery Knee Score	39	67.7	87.3	3.4 (I)	4.9% (I)
		C: Hylan G‐F 20		34	70.1	86.3
Karatosun 2005a	14‐26 wk	E: Orthovisc	Hospital for Special Surgery Knee Score	37	67.7	84.7	1.4 (I)	2.0% (I)
		C: Hylan G‐F 20		34	70.1	85.7
Karatosun 2005	45‐52 wk	E: Orthovisc	Hospital for Special Surgery Knee Score	30	67.7	86.6	2.3 (I)	3.3% (I)
		C: Hylan G‐F 20		32	70.1	86.7
Karatosun 2005a	1‐4 wk	E: Orthovisc	Pain during activity (HSSKS)	39	4.4	11.2	0.8 (I)	15.4% (I)
		C: Hylan G‐F 20		40	5.2	11.2
Karatosun 2005a	5‐13 wk	E: Orthovisc	Pain during activity (HSSKS)	39	4.4	11.3	1.8 (I)	34.6% (I)
		C: Hylan G‐F 20		34	5.2	10.3
Karatosun 2005a	14‐26 wk	E: Orthovisc	Pain during activity (HSSKS)	37	4.4	10.5	0.7 (I)	13.5% (I)
		C: Hylan G‐F 20		34	5.2	10.6
Karatosun 2005a	45‐52 wk	E: Orthovisc	Pain during activity (HSSKS)	30	4.4	10.8	0.5 (I)	9.6% (I)
		C: Hylan G‐F 20		32	5.2	11.1
Karatosun 2005a	1‐4 wk	E: Orthovisc	Pain at rest (HSSKS)	39	9.1	14.1	0.1 (I)	1.2% (I)
		C: Hylan G‐F 20		40	8.1	13.0
Karatosun 2005a	5‐13 wk	E: Orthovisc	Pain at rest (HSSKS)	39	9.1	13.4	‐0.8 (W)	‐9.9% (W)
		C: Hylan G‐F 20		34	8.1	13.2
Karatosun 2005a	14‐26 wk	E: Orthovisc	Pain at rest (HSSKS)	37	9.1	13.2	‐1.3 (W)	‐16.0% W)
		C: Hylan G‐F 20		34	8.1	13.5
Karatosun 2005a	45‐52 wk	E: Orthovisc	Pain at rest (HSSKS)	30	9.1	13.4	‐0.7 (W)	‐8.6% (W)
		C: Hylan G‐F 20		32	8.1	13.1
Karatosun 2005a	1‐4 wk	E: Orthovisc	Pain during climbing stairs (HSSKS)	39	2.1	3.5	0	0%
		C: Hylan G‐F 20		40	2.1	3.5
Karatosun 2005a	5‐13 wk	E: Orthovisc	Pain during climbing stairs (HSSKS)	39	2.1	3.5	‐0.1 (W)	‐4.8% (W)
		C: Hylan G‐F 20		34	2.1	3.6
Karatosun 2005a	14‐26 wk	E: Orthovisc	Pain during climbing stairs (HSSKS)	37	2.1	3.0	‐0.1 (W)	‐4.8% (W)
		C: Hylan G‐F 20		34	2.1	3.1
Karatosun 2005a	45‐52 wk	E: Orthovisc	Pain during climbing stairs (HSSKS)	30	2.1	3.0	‐0.4 (W)	‐19.0% (W)
		C: Hylan G‐F 20		32	2.1	3.4